Provided by Tiger Trade Technology Pte. Ltd.

Gossamer Bio Inc.

0.3748
-0.0067-1.76%
Post-market: 0.37680.0020+0.53%18:16 EDT
Volume:9.44M
Turnover:3.62M
Market Cap:87.96M
PE:-0.50
High:0.4108
Open:0.3744
Low:0.3637
Close:0.3815
52wk High:3.87
52wk Low:0.3213
Shares:234.70M
Float Shares:211.00M
Volume Ratio:0.44
T/O Rate:4.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7455
EPS(LYR):-0.7455
ROE:-783.37%
ROA:-41.86%
PB:-0.72
PE(LYR):-0.50

Loading ...

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and PepGen Inc. (PEPG)

TIPRANKS
·
Feb 25

NASD Most Active Issues

Dow Jones
·
Feb 25

These Analysts Slash Their Forecasts On Gossamer Bio

Benzinga_recent_news
·
Feb 24

Gossamer Bio Cut to Underweight From Overweight by Barclays

Dow Jones
·
Feb 24

Gossamer Bio Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
Feb 24

Gossamer Bio Shares Down 7.8% Premarket After at Least Two Brokerages Downgrade Stock

THOMSON REUTERS
·
Feb 24

Wedbush Downgrades Gossamer Bio to Neutral From Outperform, Cuts Price Target to $1 From $6

MT Newswires Live
·
Feb 24

Gossamer Bio Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $1 From $6

THOMSON REUTERS
·
Feb 24

Gossamer Bio downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
Feb 24

Gossamer Bio downgraded to Underweight from Overweight at Barclays

TIPRANKS
·
Feb 24

Block & Leviton Probes Gossamer Bio for Securities Law Violations

Reuters
·
Feb 24

Gossamer Bio Phase 3 miss adds regulatory uncertainty, says Leerink

TIPRANKS
·
Feb 23

BUZZ-Gossamer Bio falls after experimental lung condition drug fails in trial

Reuters
·
Feb 23

Gossamer Bio Shares Plunge 80% Premarket After Co's Lung Condition Drug Fails to Meet Late-Stage Trial Goal

THOMSON REUTERS
·
Feb 23

Gossamer Bio reports Phase 3 PROSERA topline results for seralutinib in pulmonary arterial hypertension

Reuters
·
Feb 23

Gossamer Bio Announces Topline Results From the Phase 3 Prosera Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

THOMSON REUTERS
·
Feb 23

Gossamer Bio Inc - Plans to Meet With U.S. FDA to Discuss Path Forward

THOMSON REUTERS
·
Feb 23

Gossamer Bio Inc - Seralutinib Shows +13.3M Improvement in 6Mwd at Week 24

THOMSON REUTERS
·
Feb 23

Gossamer: Disappointed to Narrowly Missed Stringent Prespecified Statistical Threshold for Primary Endpoint, Result Clears Traditional 0.05 P-Value

THOMSON REUTERS
·
Feb 23

Gossamer Bio Inc: Seralutinib Generally Well Tolerated ,Safety Consistent With Prior Experience

THOMSON REUTERS
·
Feb 23